Clinical trial · Observational
Optimising Cardiovascular Health in Endometrial Cancer Survivors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Women successfully treated for endometrial cancer remain at higher risk of dying than women without a history of the disease, predominately due to an excess risk of cardiovascular disease. Our previous work has shown that endometrial cancer survivors are more likely to have undiagnosed and undertreated cardiovascular risk factors than the general population, despite being seen regularly by medical professionals. This study aims to determine the impact of optimising modifiable cardiovascular risk factors in endometrial cancer survivors on their quality of life and to identify barriers to lifestyle modifications.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiovascular Diseases | — | UNRESOLVED | — |
| Endometrial Cancer | Malignant Endometrial Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cardiovascular Agents, Other | Drug | — | UNRESOLVED |
| Lifestyle modification | Behavioral | — | UNRESOLVED |
| QRISK 3 Score | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Endometrial cancer survivors
- interventionNames
- Behavioral: Lifestyle modification
- Drug: Cardiovascular Agents, Other
- Other: QRISK 3 Score
Primary outcomes (2)
- measure
- To assess the change in quality of life in endometrial cancer survivors by treating modifiable cardiovascular risk factors over a period of 12 months.
- timeFrame
- Baseline, 3 months, 6 months and 12 months.
- description
- The generic 36-Item Short Form Survey (SF-36) questionnaire focused on general wellbeing and quality of life. A variety of responses are used in this questionnaire. Some use numeric indicators, with a lower overall score meaning a worse outcome and a higher score meaning a better outcome.
- measure
- To assess the change in quality of life in endometrial cancer survivors by treating modifiable cardiovascular risk factors over a period of 12 months.
- timeFrame
- Baseline, 3 months, 6 months and 12 months.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 110 Years
Show eligibility criteria text
Inclusion Criteria: * Previous treatment for endometrial cancer within the last four years * Able to consent to participation in the study Exclusion Criteria: * Currently undergoing treatment for endometrial cancer recurrence * Anticipated life expectancy \<12 months * To cease routine surveillance in next 12 months * Not registered with a General Practitioner (GP)
References
Publications (0)
Data not yet available